Malignant neoplasm is believed to be one of the extended conditions of neoplasm. It is a form of cancer that develops an abnormal growth of tissues usually leading to the formation of a tumor. The primary cause of this disease is understood as damaging of DNA under certain circumstances that further escalates to a stage of cancer. The very beginning of malignant neoplasm is the occurrence of abnormal patterns of growth in the tissue known as dysplasia or metaplasia.
Higher Prevalence of Malignant Neoplasm in Geriatric Population Driving the Market Growth
The global cancer incidences have increased to a considerable number over the past few decades owing to a rise in the geriatric population, increasing life expectancy and changing lifestyle. In addition, factors such as advanced cancer diagnostics and early initiation of the treatment are fuelling the global malignant neoplasm therapeutics market. Development of targeted therapies are revolutionizing the conventional concepts of cancer treatment and are likely to get higher preference in the coming years. Moreover, a higher success ratio of these latest cancer drugs compared to traditional anti-carcinogenic treatment is expected to further drive the market growth in the near future. These latest drugs are capable of countering more than one type of cancer. For example ‘imatinib’, which was first developed for treating a single type of cancer was later found effective on multiple cancer types.
Novelty in cancer treatment has significantly influenced the present treatment models. However, a complete cure for the disease is still not ascertained. Further, many of the advanced treatment models are often expensive and only available in developed regions of the world. In some case, delay in integration of the novel drugs into current treatment methods limit the options for the patient. Other factors such as price risk and credibility of the drugs are few of the other concerns for the market.
Over the years, the subject of oncology has received paramount attention from biomedical researchers, health care experts and pharmaceutical manufacturers. Owing to a severe need for effective treatment of cancer, heavy investments are being made in further research and development of the particular subject. Many of the pharmaceutical companies such as Novartis International AG and Pfizer Inc. are introducing a range of anti-carcinogenic drugs under their brand names promising to be more efficient. The global malignant neoplasm treatment market has become increasingly competitive in the recent years with more player joining in. Currently, most drug manufacturers offer two primary cancer therapeutic programs, namely cytostatic hormonal treatments and antineoplastics.
Malignant Neoplasm Therapeutics Market: Regional Segmentation
On the basis of region, the global malignant neoplasm therapeutics market has been segmented into six key regions namely North America, Western Europe, Eastern Europe, Asia Pacific (APAC), Latin America, and the Middle East & Africa. North America is considered as one of the largest market of malignant neoplasm therapeutics owing to a strong presence of drug manufacturers in the region and availability of advanced healthcare facilities. In terms of value, the U.S accounts for a healthy portion of the global malignant neoplasm therapeutics market attributed to the growing demand for cancer treatment in the country. In addition, Europe is one of the other regions where the market is growing at a considerable rate and is expected to continue a similar in trend in the coming years.
Few of the key players identified in the global malignant neoplasm therapeutics market include F. Hoffmann-La Roche AG, Novartis International AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Takeda Pharmaceutical Company Ltd, Pfizer Inc. Bayer AG, Amgen, AbbVie Inc and Celgene Corporation.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Malignant Neoplasm Therapeutics Market during 2016- 2024
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453